Trading Options with an Edge
Select Page

Member Content

Option Trade Looks to Position for Next Large Cap Biotech M&A Target Following SeaGen

by | Jul 7, 2022

BioMarin (BMRN) bullish buys of 1350 January $105 calls $5.10 to $5.25, name that has 1350 January $90/$80 bull risk reversals in open interest from a trade last April. BMRN showing strength as it moves out of a long value zone and the $15.6B Biotech trading 8.3X Sales could be the next large cap Biotech M&A target, revenues seen rising 15-20% annually the next few years. Recently, the EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending conditional marketing authorization for BioMarin’s Valrox for adults with severe hemophilia A, a nice kicker to revenue growth. BMRN will resubmit a BLA in September for Roctavian while VOXZOGO is off to a strong start. 

Not a Member yet?
Subscribe to
OptionsHawk Premium
Subscribe

Options Hawk Max

$300 | 30 days

  • Options Hawk Trading Hub Live Chat
  • Hawk’s Market Blitz
  • Spotlight Trades (2 Per Week)
  • Market Recap
  • Weekly Earnings Snapshots
  • Live Mock Portfolio
  • 1 on 1 Access
  • Hawk’s Trader Toolbox
  • Street Research
  • OptionsHawk Research
  • Daily Options Radar
  • OptionHawk’s Weekly Radar Report
  • Options Hawk Market Outlook Access
  • Daily Earnings Grid
  • Weekly and Monthly OpEx Sheets
  • Notable Options Database
  • OptionsHawk Quarterly Market Brief

More About this Plan

Options Hawk Elite

$149 | 30 days

  • Hawk’s Market Blitz
  • Spotlight Trades (2 Per Week)
  • Market Recap
  • Weekly Earnings Snapshots
  • OptionsHawk Research
  • Daily Options Radar
  • OptionHawk’s Weekly Radar Report
  • Options Hawk Market Outlook Access
  • Daily Earnings Grid
  • OptionsHawk Quarterly Market Brief

More About this Plan